Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

Investigational New Drugs

Volumn 26, Issue 5, 2008, Pages 483-488

  Vansteenkiste, Johan ^a   Van Cutsem, Eric ^a   Dumez, Herlinde ^a   Chen, Cong ^b   Ricker, Justin L ^b   Randolph, Sophia S ^b   Schöffski, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Breast cancer; Colorectal cancer; HDAC; Histone deacetylase inhibitor; Non small lung cancer; SAHA; Suberoylanilide hydroxamic acid; Vorinostat; Zolinza

Indexed keywords

ANTHRACYCLINE; FLUOROPYRIMIDINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; OXALIPLATIN; TAXANE DERIVATIVE; VORINOSTAT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLURRED VISION; BREAST CANCER; CACHEXIA; CANCER PAIN; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DISEASE COURSE; DOSE LIMITING TOXICITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HEALTH; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PARAMETER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BLEEDING; UPPER ABDOMINAL PAIN; VERTIGO; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE;

EID: 50249095068     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9131-6     Document Type: Article

References (21)

1. M Dokmanovic C Clarke PA Marks 2007 Histone deacetylase inhibitors: overview and perspectives Mol Cancer Res 5 981 989
2. WK Rasheed RW Johnstone HM Prince 2007 Histone deacetylase inhibitors in cancer therapy Expert Opin Investig Drugs 16 659 678
3. WS Xu RB Parmigiani PA Marks 2007 Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 5541 5552
4. M Duvic R Talpur X Ni C Zhang P Hazarika C Kelly JH Chiao JF Reilly JL Ricker VM Richon SR Frankel 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31 39
5. EA Olsen YH Kim TM Kuzel TR Pacheco FM Foss S Parker SR Frankel C Chen JL Ricker JM Arduino M Duvic 2007 Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 25 3109 3115
6. P Bali M Pranpat R Swaby W Fiskus H Yamaguchi M Balasis K Rocha HG Wang V Richon K Bhalla 2005 Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2 Clin Cancer Res 11 6382 6389
7. LM Butler DB Agus HI Scher B Higgins A Rose C Cordon-Cardo HT Thaler RA Rifkind PA Marks VM Richon 2000 Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res 60 5165 5170
8. N Komatsu N Kawamata S Takeuchi D Yin W Chien CW Miller HP Koeffler 2006 SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells Oncol Rep 15 187 191
9. PN Munster T Troso-Sandoval N Rosen R Rifkind PA Marks VM Richon 2001 The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells Cancer Res 61 8492 8497
10. WK Kelly OA O'Connor LM Krug JH Chiao M Heaney T Curley B MacGregore-Cortelli W Tong JP Secrist L Schwartz S Richardson E Chu S Olgac PA Marks H Scher VM Richon 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 3923 3931
11. WK Kelly VM Richon O O'Connor T Curley B MacGregor-Curtelli W Tong M Klang L Schwartz S Richardson E Rosa M Drobnjak C Cordon-Cordo JH Chiao R Rifkind PA Marks H Scher 2003 Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 3578 3588
12. G Garcia-Manero H Yang C Bueso-Ramos A Ferrajoli J Cortes WG Wierda S Faderl C Koller G Morris G Rosner A Loboda VR Fantin SS Randolph JS Hardwick JF Reilly C Chen JL Ricker JP Secrist VM Richon SR Frankel HM Kantarjian 2008 Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes Blood 111 1060 1066
13. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
14. Y Fujiwara N Yamamoto K Yamada F Koizumi T Shimoyama K Nishio T Otsuki SR Frankel T Tamura 2007 Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with solid tumors J Thorac Oncol 2 S459
15. K Tobinai T Watanabe S Kobayashi S Yamasaki Y Morita-Hoshi H Yokoyama Y Morishima H Kato SR Frankel T Otsuki 2007 Phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with non-Hodgkin's lymphoma in Japan J Clin Oncol 25 703s
16. SS Ramalingam RA Parise RK Ramananthan TF Lagattuta LA Musguire RG Stoller DM Potter AE Argiris JA Zwiebel MJ Egorin CP Belani 2007 Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with Carboplatin and Paclitaxel for advanced solid malignancies Clin Cancer Res 13 3605 3610
17. WR Schelman J Kolesar K Schell R Marnocha J Eickhoff D Alberti G Wilding H Bailey 2007 A phase I study of vorinostat in combination with bortezomib in refractory solid tumors J Clin Oncol 25 3573
18. A Daud M Schmitt D Marchion E Bicaku S Minton M Egorin J Zwiebel A Chiappori D Sullivan P Munster 2007 Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies J Clin Oncol 25 3502
19. P Tang A Oza C Townsley L Siu G Pond P Sarveswaran S Webster J Zwiebel E Chen 2007 A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors J Clin Oncol 25 3576
20. MG Fakih L Pendyala P Smith P Creaven K Toth J Zwiebel S Frankel A Litwin L Huffman M Egorin 2007 A phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC) J Clin Oncol 25 4088
21. OA O'Connor ML Heaney L Schwartz S Richardson R Willim B Macgregor-Cortelli T Curly C Moskowitz C Portlock S Horwitz AD Zelenetz S Frankel V Richon P Marks WK Kelly 2006 Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24 166 173